PMID- 26849158
OWN - NLM
STAT- MEDLINE
DCOM- 20161223
LR  - 20181113
IS  - 1532-0987 (Electronic)
IS  - 0891-3668 (Print)
IS  - 0891-3668 (Linking)
VI  - 35
IP  - 5
DP  - 2016 May
TI  - Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections 
      in Children and Adolescents.
PG  - 511-6
LID - 10.1097/INF.0000000000001076 [doi]
AB  - BACKGROUND: This subgroup analysis of the European Cubicin Outcomes Registry 
      Experience evaluated the safety and effectiveness of daptomycin in children and 
      adolescent patients (<18 years). METHODS: Clinical outcomes at the end of therapy 
      were assessed as success (cured or improved), failure or nonevaluable. Safety was 
      assessed for up to 30 days post treatment. RESULTS: Eighty-one children and 
      adolescent patients were included in this study. The most common primary 
      infections were bacteremia (19.8%), complicated skin and soft-tissue infection 
      (18.5%), osteomyelitis (13.6%), endocarditis (12.3%), foreign body/prosthetic 
      infection (12.3%), uncomplicated skin and soft-tissue infection (9.9%) and other 
      (13.6%). Daptomycin doses ranged from 4 to >10 mg/kg/day. Median duration of 
      therapy was 12.5 (interquartile range, 7-25; mean, 16.7; standard deviation, 
      12.8) days. Staphylococcus aureus (46.7%) was the most commonly isolated pathogen 
      (23.8% methicillin-resistant S. aureus). Forty-nine (60.5%) patients completed 
      daptomycin therapy without further antibiotics, 27 (33.3%) switched to another 
      antibiotic, 4 (4.9%) discontinued because of adverse events (AEs) and 1 (1.2%) 
      discontinued because of other reason. Overall, 75 (92.6%; 95% confidence 
      interval: 95.2-100.0%) patients achieved clinical success; 39 of 41 (95.1%) 
      patients receiving daptomycin monotherapy and 36 of 40 (90.0%) patients receiving 
      concomitant antibiotics. Six (7.4%) patients reported AEs, including 1 patient 
      with increased blood creatine phosphokinase. Three (3.7%) patients had serious 
      AEs; 1 (1.2%) had a serious AE possibly related to daptomycin. CONCLUSION: 
      Daptomycin, alone or combined with other antibiotics and/or surgery, demonstrated 
      high clinical success rates against a wide variety of infections and was well 
      tolerated in children and adolescents.
FAU - Syriopoulou, Vassiliki
AU  - Syriopoulou V
AD  - From the *First Department of Pediatrics, University of Athens, Aghia Sophia 
      Children's Hospital, Athens, Greece; daggerDepartment of Orthopaedic Surgery, 
      University of Thessalia, Larissa, Greece; double daggerOncology National Scientific Center, 
      Moscow, Russia;  section signA.O.R.N. Monaldi-U.O.C. Medicina Infettivologica e dei 
      Trapianti, Napoli, Italy;  paragraph signBiostatistics and Statistical Sciences, Novartis 
      Healthcare Pvt. Ltd., Hyderabad, India; and  ||Global Medical Affairs, Novartis 
      Pharmaceuticals Corporation, East Hanover, NJ.
FAU - Dailiana, Zoe
AU  - Dailiana Z
FAU - Dmitriy, Nisichenko
AU  - Dmitriy N
FAU - Utili, Riccardo
AU  - Utili R
FAU - Pathan, Rashidkhan
AU  - Pathan R
FAU - Hamed, Kamal
AU  - Hamed K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatr Infect Dis J
JT  - The Pediatric infectious disease journal
JID - 8701858
RN  - 0 (Anti-Bacterial Agents)
RN  - NWQ5N31VKK (Daptomycin)
SB  - IM
MH  - Adolescent
MH  - Anti-Bacterial Agents/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Daptomycin/adverse effects/*therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology/pathology
MH  - Female
MH  - Gram-Positive Bacterial Infections/*drug therapy
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Treatment Outcome
PMC - PMC4830747
COIS- Funding for the study and editorial assistance was provided by Novartis Pharma 
      AG. V. Syriopoulou had received grant from Novartis. N. Dmitriy has no funding or 
      conflicts of interest to disclose. Z. Dailiana had received honoraria for 
      consultancy services and support for travel to meetings from Novartis. R. Utili 
      had received grant support and travel grants to attend meetings from Novartis. He 
      also provided consultancy services and lectures for Novartis and was a member of 
      the board of Novartis. R. Pathan is an employee of Novartis Healthcare Pvt. Ltd. 
      K. Hamed is an employee of Novartis Pharmaceuticals Corporation.
EDAT- 2016/02/06 06:00
MHDA- 2016/12/24 06:00
PMCR- 2016/04/13
CRDT- 2016/02/06 06:00
PHST- 2016/02/06 06:00 [entrez]
PHST- 2016/02/06 06:00 [pubmed]
PHST- 2016/12/24 06:00 [medline]
PHST- 2016/04/13 00:00 [pmc-release]
AID - 10.1097/INF.0000000000001076 [doi]
PST - ppublish
SO  - Pediatr Infect Dis J. 2016 May;35(5):511-6. doi: 10.1097/INF.0000000000001076.